Association of long-term PPI use with low-risk gastric neuroendocrine tumor

#3558

Introduction: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occure sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated tumors.

Aim(s): Define the classification of gastric NETs associated with long-term proton pump inhibitor (PPI) use.

Materials and methods: Retrospective study of all gastric NETs seen at MCC between 1/2008 and 9/2021. Patients (pts) with clear type I and type II gastric carcinoids, and poorly differentiated NECs were excluded. Data was collected on pts with type 3 gastric NETs, including PPI use, gastrin levels (both on and off PPI), pathologic features, and presence of metastatic disease.

Conference:

Presenting Author:

Authors: Al-Toubah T, Pelle E, Strosberg J,

Keywords: gastric carcinoid, ppi, gastric, NET, type 2, type 3, type 1,